Krystal Biotech, Inc. (KRYS)
Market Cap | 5.07B |
Revenue (ttm) | 95.95M |
Net Income (ttm) | 57.16M |
Shares Out | 28.56M |
EPS (ttm) | 1.88 |
PE Ratio | 94.47 |
Forward PE | 66.68 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 266,137 |
Open | 181.82 |
Previous Close | 182.27 |
Day's Range | 177.36 - 183.37 |
52-Week Range | 93.95 - 191.78 |
Beta | 0.89 |
Analysts | Strong Buy |
Price Target | 175.67 (-1.09%) |
Earnings Date | Aug 5, 2024 |
About KRYS
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cys... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for KRYS stock is "Strong Buy." The 12-month stock price forecast is $175.67, which is a decrease of -1.09% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/v/7/conf14-2431610.jpg)
Krystal Biotech to Present at the American Thoracic Society 2024 International Conference
PITTSBURGH, May 15, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new pre...
![](https://cdn.snapi.dev/images/v1/a/h/conf15-2417513.jpg)
Krystal Biotech to Present at BofA Securities 2024 Health Care Conference
PITTSBURGH, May 08, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the B...
![](https://cdn.snapi.dev/images/v1/l/z/press4-2411744.jpg)
Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates
Net product revenue of $45.3 million in 1Q and $95.9 million since August First patient dosed in inhaled KB707 study for locally advanced or metastatic tumors of the lung Received Fast Track Designati...
![](https://cdn.snapi.dev/images/v1/d/f/conf2-2405510.jpg)
Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
PITTSBURGH, May 02, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new pre...
![](https://cdn.snapi.dev/images/v1/b/x/conf14-2393830.jpg)
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 202...
![](https://cdn.snapi.dev/images/v1/u/2/press13-2382665.jpg)
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
• Received Fast Track Designations for both inhaled and intratumoral KB707 PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biote...
![](https://cdn.snapi.dev/images/v1/n/g/conf15-2355970.jpg)
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
Intratumoral delivery of HSV-1 encoded IL-12 and IL-2 enhanced local and systemic effector T-cell responses in cold tumor preclinical model Intratumoral delivery of HSV-1 encoded IL-12 and IL-2 enhanc...
![](https://cdn.snapi.dev/images/v1/h/o/conf20-2297996.jpg)
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
PITTSBURGH, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the T...
![](https://cdn.snapi.dev/images/v1/2/7/press15-2293321.jpg)
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
• Net product revenue of $42.1M in 4Q and $50.7M for the year • New England Journal of Medicine publication of the use of B-VEC eyedrop formulation • Reached alignment with FDA to enable approval o...
![](https://cdn.snapi.dev/images/v1/3/r/conf7-2283045.jpg)
Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, will report its fourth quarter and full year 2023 financia...
![](https://cdn.snapi.dev/images/v1/r/g/press20-2272962.jpg)
Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
• FDA clears IND and Phase 1 (KYANITE-1) clinical trial expected to be initiated in 1H 2024 PITTSBURGH, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commer...
![](https://cdn.snapi.dev/images/v1/n/q/press6-2266548.jpg)
Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa
• Initial clinical data suggest the potential of B-VEC to treat lesions in the eye of DEB patients and additional applications of Krystal's HSV-1 platform to treat ocular diseases
![](https://cdn.snapi.dev/images/v1/k/g/conf6-2254967.jpg)
Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference
PITTSBURGH, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the G...
![](https://cdn.snapi.dev/images/v1/q/i/press8-2216016.jpg)
Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®
PITTSBURGH, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization...
![](https://cdn.snapi.dev/images/v1/a/e/press1-2201510.jpg)
Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)
PITTSBURGH, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization...
![](https://cdn.snapi.dev/images/v1/z/d/press13-2171856.jpg)
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
PITTSBURGH, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization...
![](https://cdn.snapi.dev/images/v1/6/y/conf2-2149287.jpg)
Krystal Biotech to Present at the Stifel 2023 Healthcare Conference
PITTSBURGH, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization...
![](https://cdn.snapi.dev/images/v1/r/0/press12-2141112.jpg)
Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update
• 284 VYJUVEK Patient Start Forms and $8.6 million in VYJUVEK U.S. net product revenue as of the end of the third quarter • Cohort 1 completed in Phase 1 clinical trial of KB407 for the treatment ...
![](https://cdn.snapi.dev/images/v1/z/p/conf7-2127514.jpg)
Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023
PITTSBURGH, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization...
![](https://cdn.snapi.dev/images/v1/l/j/conf11-2081393.jpg)
Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference
PITTSBURGH, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercializatio...
![](https://cdn.snapi.dev/images/v1/q/u/press8-2072726.jpg)
Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency
• Orphan Drug Designation Granted to KB408 PITTSBURGH, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the ...
![](https://cdn.snapi.dev/images/v1/x/k/conf7-2053157.jpg)
Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
PITTSBURGH, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercializatio...
![](https://cdn.snapi.dev/images/v1/1/g/press2-2048864.jpg)
Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
PITTSBURGH, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercializatio...
![](https://cdn.snapi.dev/images/v1/2/e/press14-2030282.jpg)
Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million
PITTSBURGH, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), a commercial-stage biotechnology company focused on the discovery, development, and commercializatio...
![](https://cdn.snapi.dev/images/v1/a/k/press3-2009389.jpg)
Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights
• VYJUVEK™ approved in the U.S. as the first and only topical redosable gene therapy for the treatment of dystrophic epidermolysis bullosa